Regeneron has signed a collaboration deal potentially worth $1 billion with RNAi experts Alnylam Pharmaceuticals, to develop and commercialise drugs targeting eye, central nervous system (CNS ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback